Full Press Release Details
Neuphoria Provides First Quarter 2025 Business Updates
BURLINGTON, Mass., May 20, 2025 (GLOBE NEWSWIRE) --
Neuphoria Therapeutics Inc. (Nasdaq: NEUP) ("Neuphoria" or the "Company"), a clinical-stage biotechnology company
developing impactful treatments for neuropsychiatric disorders, today provides business updates for the First Quarter of 2025.
"The first quarter of 2025 marked steady progress
across our pipeline," said Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Neuphoria. "Our lead internal program
BNC210 continues to enroll into a the AFFIRM-1 Phase 3 study in Social Anxiety Disorder, and we are planning to release topline data in
Q3 this year. We're also very pleased to see our partnered asset, MK-1167, continue its momentum in the Merck-led Phase 2 trial
in Alzheimer's disease."
FOR FURTHER INFORMATION PLEASE CONTACT:
About Neuphoria Therapeutics Inc.
Neuphoria (Nasdaq: NEUP) is a clinical-stage biotechnology company dedicated
to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. Neuphoria is advancing its
lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the 7 nicotinic acetylcholine receptor,
for the acute, "as needed" treatment of social anxiety disorder (SAD) and for chronic treatment of post-traumatic stress disorder
(PTSD). BNC210 is a first-of-its-kind, well-tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter
balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive
impairment, or addiction. In addition, Neuphoria has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United
States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease
and other central nervous system conditions. Neuphoria's pipeline also includes the 7 nicotinic acetylcholine receptor next generation
and the Kv3.1/3.2 preclinical programs, both in the lead optimization development stage.
Forward-Looking Statements
Neuphoria cautions that statements included in this press release that
are not a description of historical facts are forward-looking statements. Words such as "may," "could," "will,"
"would," "should," "expect," "plan," "anticipate," "believe,"
"estimate," "intend," "predict," "seek," "contemplate," "potential,"
"continue" or "project" or the negative of these terms or other comparable terminology are intended to identify
forward-looking statements. The forward-looking statements are based on our current beliefs, plans, burn rate and expectations. Certain
forward-looking statements, including (without limitation) about (1) Neuphoria's ability to develop and expand its business, successfully
complete development of its current product candidates, the timing of commencement and/or completion of various clinical trials and receipt
of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for
drugs to treat CNS diseases and pain conditions, (3) Neuphoria's financial resources, and (4) assumptions underlying any such statements.
The inclusion of forward-looking statements should not be regarded as a representation by Neuphoria that any of its plans will be achieved.
Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements
due to a number of important factors. Certain forward-looking statements involve contracts, licenses and arrangements involving third
parties and their respective clinical trial and research and development projects that are out of our control, including our agreements
with Merck and Carina. They may terminate or delay any or all such projects in their discretion pursuant to the terms of our agreements
with them, which could result in the Company not realizing any further milestone payments or further progress on the respective product
pathways. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the
Company's business and other risks described in the Company's filings with the SEC, including the Company's Annual Report
on Form 10-K, Quarterly Report on Form 10-Q, each filed with the SEC, and its other reports. Investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date hereof, and Neuphoria undertakes no obligation to revise
or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks,
uncertainties and other factors is included in Neuphoria's filings with the SEC, copies of which are available from the SEC's
website (www.sec.gov) and on Neuphoria's website (www.neuphoriatx.com) under the heading "Investor Center." All forward-looking
statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section
21E of the Private Securities Litigation Reform Act of 1995. Neuphoria expressly disclaims all liability in respect to actions taken or
not taken based on any or all the contents of this press release.